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Abstract
Purpose: This manuscript discusses the importance of establishing risk indicator monitoring guidelines for state Early
Hearing Detection and Intervention programs.
Method: Idaho Sound Beginnings (ISB) implemented a guideline which divided risk indicators associated with delayedonset hearing loss into two classes (Class A and Class B). From 2012–2013, the incidence of delayed-onset hearing loss
in the presence of Class A and Class B risk indicators were evaluated. For Class B risk indicators, ototoxic medication
exposure and family history were analyzed.
Results: Of the 10,634 infants born, 1,175 were found to have passed the newborn hearing screening and have at least
one risk indicator. Of the infants evaluated with Class A risk indicators, 21 children had an educationally significant hearing
loss. Of the 345 children who received ototoxic medications, 55 children were diagnosed with educationally significant
hearing loss. An educationally significant hearing loss was found in 10 children who returned for diagnostic evaluation
who had family history of childhood hearing loss.
Conclusion: ISB’s risk monitoring classification system has enhanced Idaho’s EHDI program by early identification of
children who are at higher risk for delayed-onset hearing loss. Early identification has ultimately led to early intervention.
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The Joint Committee on Infant Hearing (JCIH) was
established in 1969 to investigate the need for mass
screening programs in an effort to identify children
with hearing loss earlier in life. In 1973, the JCIH
recommended using criteria to identify newborns at risk
for hearing loss. Over the next five position statements,
JCIH modified the criteria based on research and
clinical findings. The suggested audiological monitoring
schedule ranged from strict (e.g., monitor hearing every
six months until the age of 3; JCIH, 2000) to lax (e.g., at
least one diagnostic evaluation by 24–30 months of age;
JCIH, 2007). The variability in the monitoring schedules
has the potential to create confusion for physicians
and audiologists. The JCIH 2007 Position Statement
recommended earlier and more frequent monitoring for
some risk indicators with higher prevalence of delayedonset hearing loss. For others, the JCIH 2007 Position
Statement indicates one monitoring appointment by
at least 24–30 months of age may be sufficient. To
efficiently implement these recommendations, the
use of a systematic approach may be appropriate.

In 2011, Idaho Sound Beginnings (ISB) developed a
classification system of the 2007 JCIH risk indicators to
provide guidance to those involved with newborn hearing
screening programs regarding when to refer infants to
pediatric audiologists for risk monitoring of delayed-onset
hearing loss. This article will discuss the development
of this classification system for the JCIH (2007) risk
indicators and initial findings after implementation within
two hospitals.
Introduction
Monitoring JCIH 2007 Risk Indicators
JCIH published the most recent position statement in 2007.
As shown in Table 1 the statement listed risk indicators
associated with permanent congenital, delayed-onset, or
progressive hearing loss in childhood. The neonatal risk
indicators were redefined to specifically include neonatal
intensive care of more than five days or any of the following
regardless of length of stay: Extracorporeal membrane
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oxygenation (ECMO), assisted ventilation, exposure to
ototoxic medications (gentamycin and tobramycin) or
loop diuretics (furosemide/Lasix), and hyperbilirubinemia
that requires exchange transfusion (JCIH, 2007). The
monitoring schedule was also redefined to include at
least one diagnostic audiology assessment by 24 to
30 months of age. Additionally, the time and number of
hearing evaluations for children with risk indicators should
be customized and individualized (JCIH, 2007), giving the
clinical judgement back to the audiologists and the medical
home. Earlier and more frequent assessments may be
indicated for some risk indicators with higher prevalence
of delayed-onset hearing loss. For others, one diagnostic
appointment may be sufficient.

The following risk indicators were listed in the JCIH 2007
Position Statement as being of greater concern for delayedonset hearing loss: caregiver concern, family history of
hearing loss, ECMO, cytomegalovirus (CMV), syndromes
associated with hearing loss, neurodegenerative
disorders, culture-positive postnatal infections associated
with sensorineural hearing loss, head trauma, and
chemotherapy. When considering only those infants in
the at-risk population who were diagnosed with hearing
loss, Hall (2007) reviewed the frequency of occurrence
of individual risk indicators associated with hearing
loss and identified six risk indicators that occurred most
frequently (as shown in Table 2). Hall (2007) highlighted
the importance of audiological professionals who work with

Table 1
JCIH 2007 Position Statement Risk Indicators
Caregiver concern regarding hearing, speech, language, or development delay
Family history of permanent childhood hearing loss
Neonatal intensive care of more than 5 days or any of the following regardless of length of stay:
extracorporeal membrane oxygenation (ECMO), assisted ventilation, exposure to ototoxic medications
(gentimycin and tobramycin) or loop diuretics (furosemide/Lasix), and hyperbilirubinemia that requires
exchange transfusion
In utero infections, such as cytomegalovirus (CMV), herpes, rubella, syphilis, and toxoplasmosis
Craniofacial anomalies, including those that involve the pinna, ear canal, ear tags, ear pits, and
temporal bone anomalies
Physical findings, such as white forelock, that are associated with a syndrome known to include a
sensorineural or permanent conductive hearing loss
Syndromes associated with hearing loss or progressive or delayed-onset hearing loss, such as
neurofibromatosis, osteopetrosis, and Usher syndrome; other frequently identified syndromes including
Waardenburg, Alport, Pendred, and Jervel and Lange-Nielson
Neurodegenerative disorders, such as Hunter syndrome, or sensory motor neuropathies, such as Friedreich
ataxia and Charcot-Marie-Tooth syndrome
Culture-positive postnatal infections associated with sensorineural hearing loss, including confirmed bacterial
and viral (especially herpes viruses and varicella) meningitis
Head trauma, especially basal skull/temporal bone fracture that requires hospitalization
Chemotherapy

Table 2
Individual Risk Indicators Associated with Hearing Loss Occurring Most and Least
Frequently (Hall, 2007)
Most frequent

Least frequent (< 10%)

Craniofacial anomalies (> 50%)

Low birth weight

Family history of childhood hearing loss (> 15%)

Hyperbilirubinemia

Severe asphyxia (> 15%)

Ototoxic medications

Congenital infections (> 15%)

ECMO

Mechanical ventilation (> 10%)

Substance abuse (maternal)

Bacterial meningitis (> 10%)
Note. ECMO = extracorporeal membrane oxygenation.
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the infant population being intimately familiar with all risk
indicators for hearing loss whether peripheral, auditory
dysfunction, or delayed onset.
In 2012, Beswick, Driscoll, and Kei systematically identified
753 publications from 1973 to March 2011 and reviewed 40
of those publications to draw evidence-based conclusions
on risk indicators and risk monitoring programs that detect
postnatal hearing loss. They found the most common risk
indicators reported were “gestational-age, low-birth weight,
toxoplasmosis, other infections, rubella, CMV, herpes
simplex virus infections, craniofacial anomalies, respirator
support, and the administration of aminoglycosides” (p.
745). Based on two of the publications reviewed, 3 to 3.5%
of infants were referred for follow-up testing due to the
presence of risk indicators defined by each study. Authors
found a strong relationship between postnatal hearing
loss and CMV, congenital diaphragmatic hernia, ECMO,
and persistent pulmonary hypertension. Conversely, a
weak link was found between postnatal hearing loss and
toxoplasmosis, pre-auricular skin tags and ear pits, and low
birth weight.
A retrospective study by Beswick, Driscoll, Kei, Khan,
and Glennon (2013) evaluated audiological findings for
2,107 children who were identified with one or more risk
indicators for hearing loss. Of children who initially passed
the newborn hearing screening but had risk indicator(s),
2.7% were diagnosed with hearing loss. A statistical
analysis identified family history and craniofacial anomalies
to be high predictors for postnatal hearing loss, whereas,
low birth weight was a low predictor.
Wood, Davis, and Sutton (2013) retrospectively examined
the effectiveness of targeted surveillance to identify
moderate-profound permanent childhood hearing
impairment in babies who passed the newborn hearing
screening in the presence of risk indicators for delayedonset hearing loss in England. England newborn hearing
screening program data (n = 2,307,880 children) was
reviewed from 2006 to 2009. Based on follow-up evaluation
of more than 38,000 infants who passed newborn hearing
screening with risk factor for delayed-onset hearing loss,
five factors were identified as most often associated with
permanent childhood hearing impairment: syndrome
(other than Down’s) associated with a hearing loss,
neonatal intensive care unit (NICU) with refer in both
ears at otoacoustic emissions (OAE) and pass in both
ears at automatic auditory brainstem response (AABR),
craniofacial anomaly, Down’s syndrome, and congenital
infection. Monitoring only these five criteria was estimated
to reduce the percentage of the birth population that
require targeted surveillance from 3% to 0.25% (Wood
et al., 2013). It was also noted that neonatal bacterial
meningitis and aminoglycoside antibiotics were not
considered in this review. Bacterial meningitis occurring
before the hearing screen is considered a contraindication
to screening and patients are referred directly for a full
audiological assessment. The protocol of England’s
newborn hearing screening program states that babies who

receive aminoglycoside and have blood levels exceeding
the therapeutic range should be referred for audiological
assessment by the prescribing pediatrician. Otherwise,
screening programs in England no longer record
aminoglycoside as a risk factor.
Kraft, Malhotra, Boerst, and Thorne (2014) evaluated the
economic impact of monitoring children with risk indicator
for delayed-onset hearing loss. University of Michigan
newborn hearing screening program data was reviewed
from 2001 to 2007. Ninety children were diagnosed with
hearing loss, including 16 children with delayed-onset
hearing loss. They concluded that a “NICU stay of greater
than 5 days and exposure to loop diuretics were not
associated with an increased risk of either congenital or
delayed-onset hearing loss” (p. 1842). Monitoring children
with these risk indicators, NICU length of stay greater than
five days, or exposure to potentially ototoxic medications,
in the absence of other risk indicators was reported to
have “increased the monitoring burden” nearly five times
which “contributes to the high cost of screening per case
identified” (p. 1842).
Vos, Senterre, Lagasse, SurdiScreen Group, and Levêque
(2015) retrospectively evaluated the clinical management
and follow-up of newborns with neonatal risk indicators of
hearing loss for the newborn screening program in Belgium
to systematically update the monitor recommendations.
The group completed a literature review of 15 years of
publications and graded the quality of evidence found in
regard to the risk indicators for delayed-onset hearing loss
as defined by the 2000 JCIH Position Statement and the
clinical experience of professionals from the Fédération
Wallonie-Bruselles. The study found congenital infections
(i.e., cytomegalovirus, toxoplasmosis, and syphilis), a
family history of hearing loss, consanguinity, malformation
syndromes, and fetal alcohol syndrome to have a high level
of evidence quality as neonatal risk indicators for hearing
loss. Additionally, hyperbilirubinemia had a moderate level
of evidence quality while very low birth weight, low Apgar
score, ototoxic drugs, and hospitalization in the NICU
had a very low or low level of evidence quality. Vos et al.
recommended monitoring all risk indicators for hearing
loss, even those with weak evidence, in order to avoid
“unidentified neonatal hearing loss” (p. 6). The authors also
recommended completing the initial hearing evaluation
for those newborns with any of these risk indicators prior
to discharge from the hospital using at least an auditory
brainstem response (ABR) to assess the entire auditory
brainstem pathway.
Review of current literature on risk indicators for delayedonset hearing loss revealed variability in which risk
indicators should be monitored, which risk indicators
have increased risk for delayed-onset hearing loss, and
variability on how and when to monitor individual risk
indicators. The JCIH 2007 Position Statement provided
guidance for Early Hearing Detection and Intervention
(EDHI) programs on which risk indicators to monitor and
which risk indicators have increased risk for delayed-
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onset hearing loss. Unfortunately, the JCIH 2007 Position
Statement did not provide concrete guidance on when
to begin monitoring (i.e., what age), how often to monitor
(i.e., months vs. years), and how long to continue
monitoring (i.e., until what age). The purpose of the ISB risk
monitoring classification system was to provide guidance to
stakeholders in Idaho newborn hearing screening programs
regarding when to refer infants for risk monitoring of
delayed-onset hearing loss.
Idaho Monitoring Risk Indicators
In October 2011, with guidance from the ISB pediatric
audiology consultant, hospitals with NICU programs in
Idaho began collecting data on early and more frequently
monitored risk indicators. Indicators with higher incidence
and earlier onset of hearing loss were classified as Class
A and all other risk indicators were classified as Class B.
This classification system was based on the JCIH 2007
Position Statement and evidence-based research on
craniofacial anomalies. The JCIH 2007 Position Statement
and additional studies (Vos et al., 2015; Beswick et al.,
2013; Wood et al., 2013) identified early and more frequent
assessment may be indicated for children with CMV
infection; syndromes associated with progressive hearing
loss, neurodegenerative disorders, trauma, or culturepositive postnatal infections associated with sensorineural
hearing loss; and for children who have received ECMO or
chemotherapy. Those risk indicators were designated Class
A. Cleft palate was also included in the Class A category
based on evidence-based research on craniofacial
anomalies from multiple publications (Beswick et al., 2013;
Helias, Chobaut, Mourot, & Lafon, 1988; Paradise, 1975;
Potsic, Cohen, Randall, & Winchester, 1979; Viswanathan,
Vidler, & Richard, 2008; Yules, 1970). All other risk
indicators identified by the JCIH 2007 Position Statement
were categorized in Class B including family history of
childhood hearing loss, other in-utero infections (not CMV),
NICU stay of greater than five days, any amount of ototoxic
exposure, any amount of mechanical ventilation, and other
craniofacial anomalies excluding cleft palate (Kraft et al.,
2014; Wood et al., 2013). See Figure 1 for Class A and
Class B lists.
The terminology of Class A and B were defined based
on a collaborative effort between a neonatologist and
a pediatric audiology consultant. The Class terms are
commonly used within the NICU environment and readily
identified by the medical community. Infants with Class
A risk indicators were recommended for evaluations by a
pediatric audiologist by 3 months of age. At a minimum,
the evaluation should include diagnostic ABR. Infants with
Class B risk indicators were recommended for a behavioral
hearing evaluation by a pediatric audiologist by 1 year of
age. Guidelines provided to Idaho pediatric audiologists
indicate, at a minimum, the evaluation should include
ear specific measurements at multiple frequencies as
recommended by the JCIH 2007 Position Statement when
evaluating a child 6 to 36 months of age
.

The purpose of the risk indicator classification system is
to allow for early identification of children with delayedonset hearing loss. In Idaho, when a child is identified
with hearing loss the diagnosing audiologist completes
the ISB audiology results form (Figure 2) and submits it
to ISB. This form also serves as a release of information
to early intervention programs within the state of Idaho
including Infant Toddler Program, Idaho Education
Services for the Deaf and the Blind, and Idaho Hands and
Voices. Therefore, the risk indicator classification system,
subsequent early diagnosis of hearing loss, and the ISB
reporting process should lead to timely enrollment in
early intervention.
Method
ISB, Idaho’s EHDI program, has been collecting data
on risk indicators since the implementation of the Idaho
EHDI program using Hi*Track data collection system.
Implementation of the Class A and Class B classification
system did not alter how data within Hi*Track was collected
or maintained. Hi*Track allows for retrospective analysis of
risk indicators based on the two-class classification system.
Idaho birthing hospitals report information regarding risk
indicators with results of each newborn hearing screening.
A positive family history of childhood hearing loss is selfreported by families. The presence of other risk indicators
is identified from a review of the infant’s medical chart.
Diagnostic audiological findings are reported to ISB by
Idaho audiologists using the ISB audiology results form
(Figure 2).
Data of infants born from January 2012 through December
2013 for two of the larger hospitals with NICU programs
in the state of Idaho were reviewed. Data on infants
who passed the newborn hearing screening and were
identified as having one or more risk indicators were
included in the review. Infants who referred on the newborn
hearing screening and had present risk indicators were
excluded from the study. Data was collected for analysis
in November 2015, all diagnostic audiological follow-up
information reported to ISB at that time was available
for review.
Results
According to ISB Hi*Track, 10,634 infants were born at the
two selected hospitals in Idaho during this time frame. Of
the 10,634 infants reviewed, 1,175 (11.04%) infants were
found to have passed the newborn hearing screening and
have at least one risk indicator in either Class A or Class
B. From these infants, 175 (1.6%) infants were found to
have passed the newborn hearing screening and have at
least one Class A risk indicator. Infants within the first group
of Class A risk indicators could also be represented in the
second group of either Class A or Class B risk indicators.
Infants with Class A risk indicators frequently have at least
one risk indicator from the Class B list which accounts
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Guidelines for
Risk Monitoring for Delayed Onset Hearing Loss

Class A: Risk indicators

*In-utero infections (congenital CMV)
*Culture Positive postnatal infection
(Bacterial and viral meningitis)
*Syndromes associated with
progressive or delayed onset hearing
loss (Neurofibromatosis,
Osteopetrosis, Usher Syndrome,
Townes-Brock)
*Syndromes associated with hearing
loss (Down syndrome and Sticklers)
*Cleft Lip/Palate
*ECMO assisted ventilation
*Head Trauma involving basal
skull/temporal fracture that requires
hospitalization
*Chemotherapy treatments
*Neurodegenerative disorders or
sensory motor neuropathies

If baby passes the newborn hearing
screening & has one or more CLASS A
risk indicator =
Recommendation for diagnostic ABR
evaluation with pediatric audiologists
by 3 months of age.

Class B: Risk indicators

*Family history of childhood hearing
loss
*In-Utero Infection (Herpes, Rubella,
Syphilis, Toxoplasmosis)
*NICU stay of greater than 5 days
*Any amount of ototoxic exposure
(aminoglycosides)
*Any amount of mechanical
ventilation
*Craniofacial anomalies involving
pinna, ear canal, ear pits and
temporal bone anomalies

If baby passes the newborn hearing
screening & has one or more CLASS B
risk indicators =
Recommendation for diagnostic
pediatric hearing evaluation by 1 year
of age.

NOTE: If baby REFERS on the newborn hearing screening after two attempts – Recommendation
for Diagnostic ABR evaluation to be completed by 3 months of age (JCIH 2007)
* Any parental/caregiver hearing concerns warrants a referral to a pediatric audiologist.
** Infants readmitted to the hospital within the first 30 days of life should be re-screened if any
risk indicators are present.
References:
Fligor BJ, Neault MW, Mullen CH, Feldman HA, Jones DT. Factors associated with sensorineural hearing loss among survivors of extracorporeal membrane
oxygenation therapy. Pediatrics 2005; 115(6):1519-1528.
Joint Committee on Infant Hearing. Year 2007 Position Statement: Principles and Guidelines for Early Hearing Detection and Intervention Programs.
Pediatrics. 2007; 120(4):898–921. doi: 10.1542/peds.2007-2333.
Van Riper, Lori A.; Kileny, Paul R. ABR Hearing Screening for High-Risk Infants. American Journal of Otology. 20(4):516-521, July 1999.

450 W. State St. Floor-5, Boise, ID 83702
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208-334-0829

Figure 1. Idaho Sound Beginnings guidelines for risk monitoring for delayed-onset hearing loss
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Figure 2. Idaho Sound Beginnings audiology results form.
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Figure 3. Reported risk indicators from Idaho Sound Beginnings Hi*Track database
in 2012 - 2013
for the crossover of the two groups. The number of risk
indicators reported from this population totaled 2,614
(Figure 3).
Of the 175 infants with Class A risk indicators, 87 returned
for comprehensive diagnostic audiology evaluations.
Of those, 25% (21 of 87 infants) were found to have
an educationally significant hearing loss. Educationally
significant hearing loss is defined as any type of hearing
loss (chronic conductive, sensorineural, or mixed hearing
loss), unilateral or bilateral, at 25 dB or greater (worse)
at one or more frequencies. Of the 25% that were
diagnosed with hearing loss, five (5.7%) were found to
have sensorineural or mixed hearing loss. The Class A
risk indicators present in these five children included two
children with cleft palate, one child with Townes Brock
syndrome, one child with Acrofacial Dysostosis, and one
child with congenital CMV. The most common Class A
indicators present in this population were syndromes (e.g.,
Down’s Syndrome) and cleft palate.
Of the 1,175 infants who passed the newborn hearing
screening and were identified as having at least one risk
indicator within Class A and Class B categories, 743 infants
received ototoxic medication, most commonly gentamicin.
Of those infants who received ototoxic medication, 345
(46.4%) returned for follow-up diagnostic audiological
evaluation and 55 (15.9%) were diagnosed with
educationally significant hearing loss, five (1.4%) of which
were sensorineural or mixed hearing loss and 50 (14.4%)
were chronic conductive hearing loss. Of the five infants
diagnosed with sensorineural or mixed hearing loss, three
presented with Class A risk indicator along with the Class
B ototoxic medication exposure. The remaining two infants
presented with additional Class B indicators along with
ototoxic medication exposure, specifically extended NICU
stay and prematurity.

Over half of the infants (n = 398; 53.6%) who were
identified as having the Class B risk indicator of ototoxic
medication exposure were lost to follow-up. If the trend
found for this population can be generalized to the
children who did not receive follow-up evaluations, then
approximately 63 infants have educationally significant
hearing losses and did not benefit from early diagnosis and
intervention.
Of the 1,175 infants who passed the newborn hearing
screening and were identified as having at least one risk
indicator, 175 infants were identified as having present
family history of permanent childhood hearing loss which
is a Class B risk indicator. Of the 175 infants, 65 (37.1%)
returned for diagnostic audiology evaluation for a lost
to follow-up rate of 62.8%. This was the highest lost to
follow-up rate of all the risk indicators present within
this population. An educationally significant hearing loss
was found in 10 (16%) of those infants that returned for
diagnostic evaluation, three of which were sensorineural
or mixed hearing loss and seven were chronic conductive
hearing loss. Additional risk indicators were present in
only one of the three infants diagnosed with sensorineural
or mixed hearing loss, indicating that family history of
permanent childhood hearing loss was the only indicator to
assist with early identification of hearing loss in these two
infants.
Age of diagnosis was reviewed in all children identified with
educationally significant hearing loss in the population.
Children with educationally significant hearing loss were
identified prior to 24 months of age. Children identified
with Class A risk indicators returned for initial audiological
evaluation at an average of 4 months of age (range = 2 to
9 months). Children identified with Class B risk indicators
returned for initial audiological evaluation at an average
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of 11.3 months of age (range = 9 to 13 months). The nine
children found to have sensorineural or mixed hearing
loss were diagnosed at an average of 12.6 months of age
(range = 4 to 24 months).
Discussion
ISB’s goal of using the risk monitoring classification system
was to identify infants with the higher risk for delayed-onset
hearing loss (i.e., Class A) and refer them to audiology
for earlier and more frequent monitoring per JCIH (2007)
recommendation. The infants with Class B indicators who
have lower incidence of delayed-onset hearing loss would
warrant less frequent monitoring. In this study, children with
a Class A risk indicator and delayed-onset hearing loss
were seen for initial evaluation by 10 months old (range =
2 to 9 months) and diagnosed by 25 months of age (range
= 4 to 24 months). One infant who was diagnosed at age
24 months was monitored for delay-onset hearing loss
beginning at 3 months of age. Due to the Class A risk factor
of cleft palate, the child was monitored every 6 months on
the recommendation of the managing audiologist. At 24
months of age a sensorineural hearing loss was diagnosed
in this child. Because of the JCIH (2007) position statement
recommendation to monitor earlier and more frequent for
some risk indicators, this hearing loss was identified. The
Class A and Class B classification system was designed
to refer children for audiological evaluation at appropriate
times based on the presence of risk indicators for delayedonset hearing loss. Once a child is initially referred for risk
indicator monitoring, it is at the discretion of the managing
audiologist to set the future monitoring schedule.
The findings of the Class B ototoxic medication exposure
in the study population align with Cone-Wesson et al.
(2000) and Van Riper and Kileny (1999; 2002), identifying
a high occurrence of the risk factor with a low prevalence
of associated hearing loss. Although a low incidence, early
identification is critical for those infants and their families
impacted by hearing loss related to ototoxic medication
exposure. Based on previous research, including Prezant
et al. (1993), damage from ototoxicity typically occurs
within the cochlea. This suggests an evaluation of cochlear
outer hair cell function is the most appropriate tool to
triage this population to determine necessity of further
audiological evaluation. OAE testing has been reported
as a non-invasive, cost-effective physiologic measure of
cochlear outer hair cell function (JCIH, 2007; Kezirian,
White, Yueh, & Sullivan, 2001). Therefore, an OAE test
using an ototoxic protocol alone could suffice as a triage
protocol for this risk indicator to determine if further
diagnostic evaluation is necessary. Implementing OAE
triage evaluation to optimize the audiology diagnostic test
protocols should be considered to decrease economic
impact and improve program efficiency.
The Class B risk indicator of family history of permanent
childhood hearing loss was the third most reported risk
indicator in this population. It is also the most frequently
reported risk indicator from the well-baby population (Hall,

2007; ISB, 2007–2013). Beswick et al. (2013) reported
that children with a family history of permanent childhood
hearing loss were nearly two times more likely to develop
a postnatal hearing loss than those without such family
history. Unfortunately, given the lost to follow-up rate of
63% within the current study population, we are potentially
missing early diagnosis of more than 17 children with
educationally significant hearing loss during this time frame.
Potential factors for lost to follow-up which have been
cited include maternal race/ethnicity, maternal smoking
during pregnancy, public insurance coverage, and area of
residence within the state (Liu, Farrell, MacNeil, Stone, &
Barfield, 2008).
A question to consider is if family history is reported by the
parents, then why is it the highest lost to follow-up rate? To
address this question, risk indicator monitoring programs
may want to consider improvement in the following two
areas: 1) explanation of criteria for family history of hearing
loss, and 2) scripts for screeners to inquire about family
history of hearing loss. If programs rely on families to
interpret family history of hearing loss then reports will more
than likely include middle ear dysfunction, presbycusis,
and noise induced hearing loss or other acquired hearing
loss not due to congenital or genetic factors. To improve
the family reported presence of family history of childhood
hearing loss and subsequently reduce the lost to followup rate for this population, scripts for screeners should
be provided which detail the criteria for family history of
hearing loss. Additionally, when the risk factor is present,
the family should be provided with an explanation of the risk
factor and why it is important to receive follow-up services.
If the high rate of diagnosing educationally significant
hearing loss in the presence of family history risk indicator
is accurate, consideration should be given to placing the
risk indicator of family history in the Class A category.
During this data review, families were provided with
information regarding the risk indicator present and the
need for future follow-up based on the risk indicator
classification system. Additionally, audiology clinics who
received the ISB referral forms attempted to contact the
families to schedule appropriate follow-up diagnostic
appointments based on the risk indicator classification
system. Attempts to contact infants listed in the Class
A classification were made by 3 months of age,
while attempts to contact infants listed in the Class B
classification were made by approximately 9 months of
age. Recently, additional steps have been implemented by
ISB to reduce the lost to follow-up rate in Idaho. A letter is
mailed to the child’s primary care physician immediately
following identification of an infant who passes their
newborn hearing screening with present risk indicators. A
letter is also mailed to the child’s parents at approximately
6 months of age reminding the parents to schedule an
appointment with a pediatric audiologist. Further research
is necessary to determine the impact, if any, on the lost to
follow-up rate with the implementation of reminder letters
from ISB to physicians and parents.
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The JCIH (2007) recommendation of completing at least
one diagnostic evaluation by 24 to 30 months of age is
fairly broad compared to the JCIH 2000 guidelines which
recommended monitoring all risk indicators every 6 months
until 3 years of age. During 2012–2013, the ISB program
used the Class A and Class B monitoring schedules and
by doing so children with sensorineural hearing loss were
identified prior to 24 months of age. Using the two-class
system schedule to provide ongoing monitoring for the
Class A risk indicators and one-time monitoring for the
Class B risk indicators reduces burden to families and all
stakeholders while maintaining an appropriate level for
those indicators that pose a higher level of risk. On average
children were diagnosed with sensorineural hearing loss
by 12 months of age. Having risk monitoring guidelines for
state EHDI programs provides structure to the JCIH (2007)
recommendations and appears to decrease the diagnosis
age for children with risk indicators for delayed-onset
hearing loss. As previously mentioned, earlier diagnosis of
delayed-onset hearing loss should lead to timely enrollment
into early intervention. Further research investigating the
impact of the risk indicator classification system on timely
enrollment into early intervention is indicated.
Summary
Use of the risk monitoring classification system has
enhanced Idaho’s EHDI program by providing access
to early identification of children who are at higher risk
for delayed-onset hearing loss. Subsequently, the early
identification of children with delayed-onset hearing loss
should lead to timely early intervention. Unfortunately, the
high lost to follow-up rate (e.g., over 60% in Idaho) for
infants with risk indicators indicates a need for ongoing
program improvement.
Monitoring for the risk indicator of ototoxic medication
exposure continues to be warranted as indicated by
previous and current research. Further research on the
potential risk of hearing loss from ototoxic medication
exposure is required. With regards to infants with only
ototoxic medication exposure, effort should be focused on
optimizing the audiology diagnostic test protocols while
considering program efficiency and economic impact.
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